ロード中...
Predictors of Response and Survival to Multikinase Inhibitors in Radioiodine Resistant Differentiated Thyroid Cancer
Sorafenib and lenvatinib are the only multikinase inhibitors (MKIs) approved for the treatment of radioactive iodine refractory differentiated thyroid cancer (RR-DTC). Although they have been demonstrated to improve progression free survival and overall response rate, the risk of toxicities is very...
保存先:
| 出版年: | J Pers Med |
|---|---|
| 主要な著者: | , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
MDPI
2021
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8306329/ https://ncbi.nlm.nih.gov/pubmed/34357141 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/jpm11070674 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|